Advertisement

Association of Genetic Variation with Gene Expression and Protein Abundance within the Natriuretic Peptide Pathway

  • David E. LanfearEmail author
  • Bipin Sunkara
  • Jia Li
  • Sharad Rastogi
  • Ramesh C. Gupta
  • Badri Padhukasahasram
  • L. Keoki Williams
  • Hani N. Sabbah
Article

Abstract

The natriuretic peptide (NP) system is a critical physiologic pathway in heart failure with wide individual variability in functioning. We investigated the genetic component by testing the association of single nucleotide polymorphisms (SNP) with RNA and protein expression. Samples of DNA, RNA, and tissue from human kidney (n = 103) underwent genotyping, RT-PCR, and protein quantitation (in lysates), for four candidate genes [NP receptor 1 (NPR1), NPR2, and NPR3 and membrane metalloendopeptidase]. The association of genetic variation with expression was tested using linear regression for individual SNPs, and a principal components (PC) method for overall gene variation. Eleven SNPs in NPR2 were significantly associated with protein expression (false discovery rate ≤0.05), but not RNA quantity. RNA and protein quantity correlated poorly with each other. The PC analysis showed only NPR2 as significant. Assessment of the clinical impact of NPR2 genetic variation is needed.

Keywords

Natriuretic peptide Heart failure Gene expression Pharmacogenomics Nesiritide Genetic polymorphisms 

Notes

Acknowledgements

We thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, MO, USA, for the use of the Tissue Procurement Core, which provided tissue, DNA, and RNA isolation services. The Siteman Cancer Center is supported in part by a NCI Cancer Center Support Grant #P30 CA91842. This work was supported by grants from the National Institutes of Health (Lanfear, HL085124 and HL103871).

Conflicts of interest

The authors declare that they have no competing interests.

Supplementary material

12265_2013_9491_MOESM1_ESM.docx (24 kb)
ESM 1 (DOCX 24 kb)

References

  1. 1.
    Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., Fullerton, H. J., Gillespie, C., Hailpern, S. M., Heit, J. A., Howard, V. J., Kissela, B. M., Kittner, S. J., Lackland, D. T., Lichtman, J. H., Lisabeth, L. D., Makuc, D. M., Marcus, G. M., Marelli, A., Matchar, D. B., Moy, C. S., Mozaffarian, D., Mussolino, M. E., Nichol, G., Paynter, N. P., Soliman, E. Z., Sorlie, P. D., Sotoodehnia, N., Turan, T. N., Virani, S. S., Wong, N. D., Woo, D., & Turner, M. B. (2012). Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation, 125(1), e2–e220. doi: 10.1161/CIR.0b013e31823ac046.PubMedCrossRefGoogle Scholar
  2. 2.
    Maeda, K., Tsutamoto, T., Wada, A., Hisanaga, T., & Kinoshita, M. (1998). Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J, 135(5 Pt 1), 825–832.PubMedCrossRefGoogle Scholar
  3. 3.
    Ellmers, L. J., Scott, N. J., Piuhola, J., Maeda, N., Smithies, O., Frampton, C. M., Richards, A. M., & Cameron, V. A. (2007). Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol, 38(1–2), 245–257. doi: 10.1677/jme.1.02138.PubMedCrossRefGoogle Scholar
  4. 4.
    Maisel, A. S., Krishnaswamy, P., Nowak, R. M., McCord, J., Hollander, J. E., Duc, P., Omland, T., Storrow, A. B., Abraham, W. T., Wu, A. H., Clopton, P., Steg, P. G., Westheim, A., Knudsen, C. W., Perez, A., Kazanegra, R., Herrmann, H. C., & McCullough, P. A. (2002). Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med, 347(3), 161–167. doi: 10.1056/NEJMoa020233.PubMedCrossRefGoogle Scholar
  5. 5.
    Pascual-Figal, D. A., Domingo, M., Casas, T., Gich, I., Ordonez-Llanos, J., Martinez, P., Cinca, J., Valdes, M., Januzzi, J. L., & Bayes-Genis, A. (2008). Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J, 29(8), 1011–1018. doi: 10.1093/eurheartj/ehn023.PubMedCrossRefGoogle Scholar
  6. 6.
    VMAC Investigators (Vasodilation in the Management of Acute CHF). (2002). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA, 287(12), 1531–1540.CrossRefGoogle Scholar
  7. 7.
    Colucci, W. S., Elkayam, U., Horton, D. P., Abraham, W. T., Bourge, R. C., Johnson, A. D., Wagoner, L. E., Givertz, M. M., Liang, C. S., Neibaur, M., Haught, W. H., & LeJemtel, T. H. (2000). Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med, 343(4), 246–253. doi: 10.1056/nejm200007273430403.CrossRefGoogle Scholar
  8. 8.
    Maisel, A. S., Clopton, P., Krishnaswamy, P., Nowak, R. M., McCord, J., Hollander, J. E., Duc, P., Omland, T., Storrow, A. B., Abraham, W. T., Wu, A. H., Steg, G., Westheim, A., Knudsen, C. W., Perez, A., Kazanegra, R., Bhalla, V., Herrmann, H. C., Aumont, M. C., & McCullough, P. A. (2004). Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J, 147(6), 1078–1084. doi: 10.1016/j.ahj.2004.01.013.PubMedCrossRefGoogle Scholar
  9. 9.
    Costello-Boerrigter, L. C., Boerrigter, G., Ameenuddin, S., Mahoney, D. W., Slusser, J. P., Heublein, D. M., Redfield, M. M., Rodeheffer, R. J., Olson, T. M., & Burnett, J. C., Jr. (2011). The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assays. Mayo Clin Proc, 86(3), 210–218. doi: 10.4065/mcp.2010.0708.PubMedCrossRefGoogle Scholar
  10. 10.
    O'Connor, C. M., Starling, R. C., Hernandez, A. F., Armstrong, P. W., Dickstein, K., Hasselblad, V., Heizer, G. M., Komajda, M., Massie, B. M., McMurray, J. J., Nieminen, M. S., Reist, C. J., Rouleau, J. L., Swedberg, K., Adams, K. F., Jr., Anker, S. D., Atar, D., Battler, A., Botero, R., Bohidar, N. R., Butler, J., Clausell, N., Corbalan, R., Costanzo, M. R., Dahlstrom, U., Deckelbaum, L. I., Diaz, R., Dunlap, M. E., Ezekowitz, J. A., Feldman, D., Felker, G. M., Fonarow, G. C., Gennevois, D., Gottlieb, S. S., Hill, J. A., Hollander, J. E., Howlett, J. G., Hudson, M. P., Kociol, R. D., Krum, H., Laucevicius, A., Levy, W. C., Mendez, G. F., Metra, M., Mittal, S., Oh, B. H., Pereira, N. L., Ponikowski, P., Tang, W. H., Tanomsup, S., Teerlink, J. R., Triposkiadis, F., Troughton, R. W., Voors, A. A., Whellan, D. J., Zannad, F., & Califf, R. M. (2011). Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med, 365(1), 32–43. doi: 10.1056/NEJMoa1100171.PubMedCrossRefGoogle Scholar
  11. 11.
    Sackner-Bernstein, J. D., Kowalski, M., Fox, M., & Aaronson, K. (2005). Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA, 293(15), 1900–1905. doi: 10.1001/jama.293.15.1900.PubMedCrossRefGoogle Scholar
  12. 12.
    Sackner-Bernstein, J. D., Skopicki, H. A., & Aaronson, K. D. (2005). Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation, 111(12), 1487–1491. doi: 10.1161/01.cir.0000159340.93220.e4.PubMedCrossRefGoogle Scholar
  13. 13.
    Luss, H., Mitrovic, V., Seferovic, P. M., Simeunovic, D., Ristic, A. D., Moiseyev, V. S., Forssmann, W. G., Hamdy, A. M., & Meyer, M. (2008). Renal effects of ularitide in patients with decompensated heart failure. Am Heart J, 155(6), 1012.e1011–1018. doi: 10.1016/j.ahj.2008.02.011.CrossRefGoogle Scholar
  14. 14.
    McKie, P. M., Sangaralingham, S. J., & Burnett, J. C., Jr. (2010). CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep, 7(3), 93–99. doi: 10.1007/s11897-010-0016-6.PubMedCrossRefGoogle Scholar
  15. 15.
    Lanfear, D. E. (2010). Genetic variation in the natriuretic peptide system and heart failure. Heart Fail Rev, 15(3), 219–228. doi: 10.1007/s10741-008-9113-y.PubMedCrossRefGoogle Scholar
  16. 16.
    Wang, T. J., Larson, M. G., Levy, D., Benjamin, E. J., Corey, D., Leip, E. P., & Vasan, R. S. (2003). Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation, 108(1), 13–16. doi: 10.1161/01.cir.0000081657.83724.a7.PubMedCrossRefGoogle Scholar
  17. 17.
    Newton-Cheh, C., Larson, M. G., Vasan, R. S., Levy, D., Bloch, K. D., Surti, A., Guiducci, C., Kathiresan, S., Benjamin, E. J., Struck, J., Morgenthaler, N. G., Bergmann, A., Blankenberg, S., Kee, F., Nilsson, P., Yin, X., Peltonen, L., Vartiainen, E., Salomaa, V., Hirschhorn, J. N., Melander, O., & Wang, T. J. (2009). Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet, 41(3), 348–353. doi: 10.1038/ng.328.PubMedCrossRefGoogle Scholar
  18. 18.
    Lanfear, D. E., Stolker, J. M., Marsh, S., Rich, M. W., & McLeod, H. L. (2007). Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther, 21(1), 55–62. doi: 10.1007/s10557-007-6007-5.PubMedCrossRefGoogle Scholar
  19. 19.
    Lanfear, D. E., Stolker, J. M., Marsh, S., Rich, M. W., & McLeod, H. L. (2006). Natriuretic peptide receptor 3 genotype modulates the relationship between B-type natriuretic peptide and left ventricular end-diastolic pressure. Therapy, 3(6), 765–771. doi: 10.2217/14750708.3.6.765.CrossRefGoogle Scholar
  20. 20.
    Lanfear, D. E., Yang, J., Leszczynski, K., & Sabbah, H. N. (2011). Natriuretic peptide receptor 3 genotype is associated with altered pharmacokinetics during nesiritide infusion. J Card Fail, 17(8), S62.CrossRefGoogle Scholar
  21. 21.
    Gauderman, W. J., Murcray, C., Gilliland, F., & Conti, D. V. (2007). Testing association between disease and multiple SNPs in a candidate gene. Genet Epidemiol, 31(5), 383–395. doi: 10.1002/gepi.20219.PubMedCrossRefGoogle Scholar
  22. 22.
    Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006). Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet, 38(8), 904–909.PubMedCrossRefGoogle Scholar
  23. 23.
    An, P., Mukherjee, O., Chanda, P., Yao, L., Engelman, C. D., Huang, C. H., Zheng, T., Kovac, I. P., Dube, M. P., Liang, X., Li, J., de Andrade, M., Culverhouse, R., Malzahn, D., Manning, A. K., Clarke, G. M., Jung, J., & Province, M. A. (2009). The challenge of detecting epistasis (G x G interactions): Genetic Analysis Workshop 16. Genet Epidemiol, 33(Suppl 1), S58–67. doi: 10.1002/gepi.20474.PubMedCrossRefGoogle Scholar
  24. 24.
    Oh, S., & Park, T. (2007). Association tests based on the principal-component analysis. BMC Proc, 1(Suppl 1), S130.PubMedCrossRefGoogle Scholar
  25. 25.
    Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., & Golani, I. (2001). Controlling the false discovery rate in behavior genetics research. Behav Brain Res, 125(1–2), 279–284.PubMedCrossRefGoogle Scholar
  26. 26.
    Vogel, C., & Marcotte, E. M. (2012). Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet, 13(4), 227–232. doi: 10.1038/nrg3185.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • David E. Lanfear
    • 1
    • 3
    Email author
  • Bipin Sunkara
    • 1
  • Jia Li
    • 2
  • Sharad Rastogi
    • 1
  • Ramesh C. Gupta
    • 1
  • Badri Padhukasahasram
    • 3
  • L. Keoki Williams
    • 3
  • Hani N. Sabbah
    • 1
  1. 1.Department of Internal Medicine, Division of Cardiology, Henry Ford Heart and Vascular InstituteHenry Ford HospitalDetroitUSA
  2. 2.Public Health SciencesHenry Ford HospitalDetroitUSA
  3. 3.Center for Health Services and Policy ResearchHenry Ford HospitalDetroitUSA

Personalised recommendations